Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
MJALLI ADNAN M M
   2. Issuer Name and Ticker or Trading Symbol
SIGA TECHNOLOGIES INC [SIGA] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
C/O TRANSTECH PHARMA, INC., 4170 MENDENHALL OAKS PARKWAY, SUITE 110		 3. Date of Earliest Transaction (Month/Day/Year)
09/30/2009
(Street)

HIGH POINT, NC 27265		 4. If Amendment, Date Original Filed(Month/Day/Year)
10/02/2009		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.0001 per share ("Common Stock") 09/30/2009   X   1,845,396 A $ 1.8784 4,317,618 I by TransTech Pharma, Inc. (2)
Common Stock 09/30/2009   F   444,666 D $ 7.8 3,872,952 I by TransTech Pharma, Inc. (2)
Common Stock 09/30/2009   S   3,851,969 (1) D $ 6.24 20,983 I by TransTech Pharma, Inc. (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant (right to buy) $ 1.8784 09/30/2009   X     1,845,396 01/08/2004 01/08/2011 Common Stock 1,845,396 $ 0 0 I By TransTech Pharma, Inc. (2)

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
MJALLI ADNAN M M
C/O TRANSTECH PHARMA, INC.
4170 MENDENHALL OAKS PARKWAY, SUITE 110
HIGH POINT, NC 27265		   X   X    

Signatures

 Adnan M. M. Mjalli   10/22/2010
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) On September 30, 2009, TransTech Pharma, Inc. sold 3,851,969 shares of Common Stock in a privately negotiated transaction to STH Partners, L.P.
(2) The shares of Common Stock and the warrants were beneficially owned by TransTech Pharma, Inc. The reporting person is the President, Chief Executive Officer and a director of TransTech Pharma, Inc. The reporting person disclaims beneficial ownership of the securities beneficially owned by TransTech Pharma, Inc. except to the extent of his pecuniary interest therein.
 
Remarks:
This amendment is filed to restate the original Form 4.  The number of shares shown in this restated Form 4 reflects an anti-dilution adjustment made pursuant to the terms of the SIGA Technologies, Inc. ("SIGA") warrant disclosed in Table II of the original Form 4 and this restated Form 4.  On September 28, 2010, SIGA announced a restatement of its financial statements in connection with a failure by SIGA to account for anti-dilution adjustments in certain warrants (including the warrants referenced in Table II).  SIGA did not timely advise the reporting persons of the effect of the anti-dilution adjustment, which was triggered before the date of the original Form 4 and which resulted in the issuance of an additional 20,983 shares of Common Stock to TransTech Pharma, Inc. as a result of the exercise of the warrants referenced in Table II.  See SIGA's Current Report on Form 8-K filed on September 28, 2010 for more information

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.